Status:
RECRUITING
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections ...
Eligibility Criteria
Inclusion
- Key
- Male or female (sex at birth).
- Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- History of at least one self-reported unsuccessful dietary effort to lose body weight.
- Key
Exclusion
- HbA1c ≥ 6.5% (48 millimole per mole \[mmol/mol\]) as measured by the central laboratory at screening.
- History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
- Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.
Key Trial Info
Start Date :
February 24 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 21 2029
Estimated Enrollment :
1150 Patients enrolled
Trial Details
Trial ID
NCT07339423
Start Date
February 24 2026
End Date
August 21 2029
Last Update
March 4 2026
Active Locations (72)
Enter a location and click search to find clinical trials sorted by distance.
1
South Broward Research LLC
Miramar, Florida, United States, 33027
2
Clinical Neuroscience Solution
Orlando, Florida, United States, 32801
3
Hope Clin Res & Wellness
Conyers, Georgia, United States, 30094
4
Endeavor Health
Skokie, Illinois, United States, 60077